State of New Jersey Common Pension Fund D Grows Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

State of New Jersey Common Pension Fund D increased its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 62.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 81,174 shares of the company's stock after acquiring an additional 31,335 shares during the period. State of New Jersey Common Pension Fund D owned approximately 0.09% of IDEAYA Biosciences worth $2,086,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Allworth Financial LP grew its holdings in IDEAYA Biosciences by 800.0% during the third quarter. Allworth Financial LP now owns 900 shares of the company's stock worth $29,000 after acquiring an additional 800 shares during the period. Covestor Ltd grew its holdings in IDEAYA Biosciences by 23,050.0% in the third quarter. Covestor Ltd now owns 926 shares of the company's stock valued at $29,000 after purchasing an additional 922 shares during the last quarter. R Squared Ltd acquired a new stake in IDEAYA Biosciences in the fourth quarter valued at $35,000. US Bancorp DE grew its holdings in IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company's stock valued at $54,000 after purchasing an additional 689 shares during the last quarter. Finally, KBC Group NV grew its holdings in IDEAYA Biosciences by 29.1% in the third quarter. KBC Group NV now owns 2,274 shares of the company's stock valued at $72,000 after purchasing an additional 513 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on IDYA shares. Oppenheimer reissued an "outperform" rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Leerink Partnrs lowered IDEAYA Biosciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, November 5th. Stephens reissued an "overweight" rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a report on Friday, February 14th. Wedbush reissued an "outperform" rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $53.58.

IDEAYA Biosciences Stock Performance

NASDAQ IDYA traded down $0.26 during trading hours on Monday, hitting $21.59. 269,040 shares of the company's stock were exchanged, compared to its average volume of 880,577. The business's 50 day moving average is $23.79 and its 200-day moving average is $29.18. IDEAYA Biosciences, Inc. has a 12-month low of $19.96 and a 12-month high of $47.72. The firm has a market capitalization of $1.89 billion, a P/E ratio of -6.53 and a beta of 0.82.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to analysts' expectations of $7.00 million. As a group, equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.